Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysisFrancesco Schettini, Daniele Generali, Carla Strina et al.|JNCI Cancer Spectrum|2025Cited by 1
Abstract P1-10-14: Bridging the gap between real-world studies (RWSs) and randomized controlled trials (RCTs) of 1st-line palbociclib+aromatase inhibitors (P+AI) in hormone receptor-positive(HR+)/HER2-negative(-) metastatic breast cancer (mBC)Daniele Generali, Giuseppe Curigliano, Sabrina Nucera et al.|Clinical Cancer Research|2025Cited by 0